Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

3.320 UNCHANGED
Official Closing Price Updated: 4:10 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 503,140
Open 3.330
Bid (Size) 3.190 (25)
Ask (Size) 3.550 (1)
Prev. Close 3.320
Today's Range 3.200 - 3.353
52wk Range 2.900 - 5.990
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
From Amneal Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-31.55%
-31.55%
1 Month
-8.54%
-8.54%
3 Month
-21.33%
-21.33%
6 Month
-33.86%
-33.86%
1 Year
-36.40%
-36.40%

More News

Read More
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 2022 Jefferies Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Recap: Amneal Pharmaceuticals Q1 Earnings
Via Benzinga
Amneal to Participate at Upcoming Investor Conferences in May
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Amneal Reports First Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals's Earnings Outlook
Via Benzinga
21 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Via Benzinga
Amneal Scores Second US Biosimilars Approval With Alymsys In Oncology
Via Benzinga
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2022 Results on May 4, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Via Benzinga
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Via Benzinga
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Amneal Pharma's Q4 Earnings Fall Short Of Expectations, Sees FY22 Sales Growth Of 7%
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Via Benzinga
Recap: Amneal Pharmaceuticals Q4 Earnings
Via Benzinga
Earnings Scheduled For March 2, 2022
Via Benzinga
Amneal Pharmaceuticals's Earnings: A Preview
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.